Journal: Journal of Sport and Health Science

Article Title: Weightlifting outperforms voluntary wheel running for improving adiposity and insulin sensitivity in obese mice

doi: 10.1016/j.jshs.2025.101100

Figure Lengend Snippet: Resistance exercise exceeds the benefits of endurance exercise in ameliorating metabolic dysfunction. Following 8 weeks of diet and exercise interventions, all mice were assessed for their metabolic function by GTT, ITT, and skeletal muscle response of Akt and AS160 phosphorylation to injection of insulin measured by Western blot. (A–C) HOMA-IR taken after an overnight fast for baseline glucose and insulin. (D and E) GTT from 0–120 min and calculated AUC; colored * indicates significant difference from NC-SED. (F and G) ITT from 0–60 min and calculated AUC; colored * indicates significant difference from NC-SED. (H–N) pAkt stimulation, AS160 S318, and AS160 T642 in hindlimb muscles before and after insulin injection and the pre–post ∆ in phosphorylation. (O and P) Total and phosphorylated 4E-BP1. (Q–T) Western results for Raptor, COX4, LC3 II/I, and ubiquitin staining. Representative western blot images inset right. Data presented as mean ± standard error of the mean. Statistical analysis performed by analysis of variance between groups: * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001. NC-SED n : 8–16 (white); HFD-SED n : 8–18 (red); HFD-R EX n : 8–16 (blue); HFD-E EX n : 8–15 (green). 4E-BP1 = Eukaryotic translation initiation factor 4E binding protein; Akt = protein kinase B; AS160 = Akt substrate 160; COX4 = cytochrome c oxidase 4; CS = citrate sythase; E EX = endurance exercise; GAPDH = glyceraldehyde 3 phosphate dehydrogenase; GTT = glucose tolerance test; HFD = high fat diet; HOMA-IR = homeostatic model assessment for insulin resistance; iAUC = integrated area under the curve; ITT = insulin tolerance test; LC3 II/I = microtubule-associated protein light chain 3; NC = normal chow; pAkt = phospho-Akt; R EX = resistance exercise; SED = sedentary; Ub = ubiquitin.

Article Snippet: Primary antibodies used for analysis were from Cell Signaling Technologies (Danvers, MA, USA) and diluted 1:1000 unless otherwise stated as follows: protein kinase B (Akt; 1:500; #4691; Cell Signaling Technologies), phospho-Akt (pAkt) S473 (1:500; #9271; Cell Signaling Technologies), Ubiquitin (#3933; Cell Signaling Technologies), microtubule-associated protein light chain 3 (LC3 II/I; #4018; Cell Signaling Technologies), cytochrome c oxidase subunit 4(COX4; #11967; Cell Signaling Technologies), Akt substrate 160 (AS160 S318; #8619; Cell Signaling Technologies), AS160 T642 (#8881; Cell Signaling Technologies), eukaryotic translation initiation factor 4E binding protein (4E-BP1; #9452; Cell Signaling Technologies), and glyceraldehyde 3 phosphate dehydrogenase (GAPDH; #2118; Cell Signaling Technologies).

Techniques: Phospho-proteomics, Injection, Western Blot, Muscles, Ubiquitin Proteomics, Staining, Binding Assay

Journal: Journal of Sport and Health Science

Article Title: Exercise training-induced extracellular miR-136-3p modulates glucose uptake and myogenesis through targeting of NRDC in human skeletal muscle

doi: 10.1016/j.jshs.2025.101091

Figure Lengend Snippet: miR-136-3p-induced increase in glucose uptake is independent of changes in canonical GLUT4 signaling pathways. The mRNA expression of GLUT4, TBC1D4, and AMPKα in primary human myotubes (A) transfected with miR-136-3p. Representative immunoblot and quantification of (B) AMPKα, (C) TBC1D4, (D) P-TBC1D4, (E) AKT, and (F) P-AKT in primary human myotubes transfected with miR-136-3p and subsequently incubated under basal or insulin-stimulated (120 nM, 1 h) conditions. Insets show representative Western blot image and total ponceau staining for loading control. Results are expressed as mean ± standard error of the mean. * p < 0.05, ** p < 0.005. AKT = protein kinase B; AMPKα = AMP-activated protein kinase α; GLUT4 = glucose transporter 4; miR = microRNA; NC = negative control; ns = no significance; P-AKT = phosphorylated AKT; P-TBC1D4 = phosphorylated TBC1D4; TBC1D4 = Tre-2/BUB2/CDC16 domain family member 4.

Article Snippet: Membranes were incubated with primary antibodies directed to NRDC (sc-137199; Santa Cruz Biotechnology, Dallas, TX, USA), AMP-activated protein kinase α (AMPKα) (#2532; Cell Signaling Technology, Danvers, MA, USA), Akt substrate of 160 kDa (AS160) (#2670; Cell Signaling Technology), phospho-AS160 (#8730; Cell Signaling Technology), protein kinase B (AKT) (#9272; Cell Signaling Technology), phospho-AKT (Ser473) (#9271; Cell Signaling Technology), or puromycin (MABE343; Merck Burlington, MA, USA).

Techniques: Protein-Protein interactions, Expressing, Transfection, Western Blot, Incubation, Staining, Control, Negative Control

Journal: Acta Pharmaceutica Sinica. B

Article Title: Neutralizing dentin sialophosphoprotein facilitates tumor vascular normalization in colorectal cancer by blocking the crosstalk between tumor cells and endothelial cells

doi: 10.1016/j.apsb.2026.06.011

Figure Lengend Snippet: DSPP/ α v β 3/MAPK signaling axis promotes tumor vessel abnormalization. (A, B) Investigating the potential regulatory functions of DSPP in CRC by the WiKi (A) and KEGG (B) pathway enrichment analysis. (C) The mitogen-activated protein kinase (MAPK)-related pathways were enriched in CRC with high DSPP expression by GSEA analysis. (D) Western blot assays showing the expression of the FAK/ERK pathway components in HUVEC treated with CM from the indicated CRC cells (E, F) Representative tubular structures formed by HUVECs treated with indicated CM from indicated HCT8/Caco-2 cells. Data are presented as mean ± SD ( n = 3). (G) Heat map demonstrates the differentially expressed genes related to angiogenesis and matrix metalloproteinase family in HUVEC treated with CM from control and sg DSPP HCT116 cells. (H) Detecting the effect of AZD6244 on the DSPP-upregulated expression of angiogenesis and matrix metalloproteinase family-related genes by real-time quantitative PCR. Data are presented as mean ± SD ( n = 4). ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001.

Article Snippet: Inhibitors, including the mitogen-activated protein kinase (MAPK) kinase inhibitor selumetinib (AZD6244, MCE, Monmouth Junction, NJ, USA) or cyclo (-RGDfK) TFA (HY-P0023A, MCE), were introduced into the cultured cells.

Techniques: Expressing, Western Blot, Control, Real-time Polymerase Chain Reaction

Journal: Acta Pharmaceutica Sinica. B

Article Title: Neutralizing dentin sialophosphoprotein facilitates tumor vascular normalization in colorectal cancer by blocking the crosstalk between tumor cells and endothelial cells

doi: 10.1016/j.apsb.2026.06.011

Figure Lengend Snippet: A schematic diagram shows the action mechanism of DSPP in regulating tumor vascular abnormalization to induce tumor metastasis. In the tumor microenvironment, IL-7F enhances the expression and secretion of DSPP in CRC. The CRC-secreted DSPP binds to the integrin α v β 3 on the endothelial cell surface and activates the downstream FAK/MAPK signaling to induce tumor vascular abnormalization, finally promote tumor metastasis.

Article Snippet: Inhibitors, including the mitogen-activated protein kinase (MAPK) kinase inhibitor selumetinib (AZD6244, MCE, Monmouth Junction, NJ, USA) or cyclo (-RGDfK) TFA (HY-P0023A, MCE), were introduced into the cultured cells.

Techniques: Expressing

Journal: Neural Regeneration Research

Article Title: Trans-spinal magnetic stimulation upregulates microglial SOCS3 to attenuate neuroinflammation in chronic constriction injury–induced neuropathic pain

doi: 10.4103/NRR.NRR-D-24-00912

Figure Lengend Snippet: rMS-induced upregulation of SOCS3 in microglia is CaMKKβ/AMPK-dependent in vitro . (A) A schematic diagram of the in vitro study. (B) Western blotting data indicating that the p-CaMKKβ protein level in BV-2 cells increased at 5 minutes after a single administration of rMS and was highest at 15 minutes post-rMS ( n = 4). (C) Western blotting data showing that the p-AMPK protein level in BV-2 cells increased significantly at 30 minutes after rMS ( n = 4). (D, E) Representative western blotting results show that STO-609 and compound C alleviated rMS-induced activation of AMPK in vitro ( n = 4). (F–H) Representative western blotting data showing that compound C abrogated rMS-induced upregulation of SOCS3 and inhibition of p38 and STAT3 in vitro ( n = 4). (I) Representative immunofluorescence images showing that rMS inhibited the translocation of NF-κB p65 (green, Alexa Fluor 488) from the cytosol to the nucleus after LPS treatment in vitro , where this effect was reversed by administration of compound C (20 μmol/mL) 0.5 hours before LPS pretreatment ( n = 3). Arrows indicate BV-2 cells. Scale bars: 10 μm. Data are expressed as mean ± SD. # P < 0.05, ## P < 0.01, vs . Control group; * P < 0.05, ** P < 0.01, **** P < 0.001, vs . LPS group; † P < 0.05, †† P < 0.01, vs. LPS + rMS group (one‐way analysis of variance followed by Tukey’s multiple comparisons tests). AMPK: Adenosine 5′-monophosphate-activated protein kinase; CaMKKβ: calmodulin-dependent protein kinase kinase beta; Compound C: an AMPK inhibitor; DAPI: 4′,6-diamidino-2-phenylindole; LPS: lipopolysaccharide; NF-κB: nuclear factor kappa-B; p-AMPK: phosphorylated AMPK(Thr172); p-CaMKKβ: phospho-CaMKKβ(Ser511); rMS: repetitive magnetic stimulation; SOCS3: suppressor of cytokine signaling 3; STAT3: transducer and activator of transcription 3; STO-609: a CaMKKβ inhibitor.

Article Snippet: Intrathecal injections of compound C, an adenosine 5′-monophosphate-activated protein kinase (AMPK) inhibitor (10 μg/10 μL; MedChemExpress, Newark, NJ, USA, Cat# HY-13418A), and SOCS3 siRNA (500 pmol/10 μL; Santa Cruz Biotechnology, Santa Cruz, CA, USA, Cat# SC-270156) were performed as described previously by Mestre et al. (1994).

Techniques: In Vitro, Western Blot, Activation Assay, Inhibition, Immunofluorescence, Translocation Assay, Control

Journal: Neural Regeneration Research

Article Title: Trans-spinal magnetic stimulation upregulates microglial SOCS3 to attenuate neuroinflammation in chronic constriction injury–induced neuropathic pain

doi: 10.4103/NRR.NRR-D-24-00912

Figure Lengend Snippet: The pain-relieving effect and upregulation of SOCS3 induced by focal rTSMS depended on the activation of AMPK. (A) Timeline diagram of CCI modeling, rTSMS treatment, mechanical withdrawal threshold assessment, and experimental analysis in rats. (B) Western blotting data illustrates that the p-AMPK protein level decreased in CCI model rats and increased in CCI + rTSMS + Vehicle rats ( n = 5). (C, D) Intrathecal injection of compound C largely prevented the pain-relieving effects of focal rTMS, when applied once or repeatedly, in rats with CCI neuropathic pain ( n = 8). (E–H) Representative western blotting results showing that compound C alleviated the rTSMS-induced activation of AMPK, increase in SOCS3, and downregulation of p38 and STAT3 ( n = 5). (I, J) Representative immunofluorescence images showing that compound C abrogated the rTSMS-induced upregulation of SOCS3 (green, Alexa Fluor 488) in the dorsal horn of the spinal cord ( n = 3). Dashed box indicates the region of interest in the dorsal horn of the spinal cord. Scale bars: 100 μm. Data are expressed as mean ± SD. # P < 0.05, ## P < 0.01, ### P < 0.001, vs. Sham + Vehicle group; * P < 0.05, ** P < 0.01, **** P < 0.0001, vs . CCI + Vehicle group; † P < 0.05, †† P < 0.01, ††† P < 0.001, †††† P < 0.0001, vs . CCI + rTSMS + Compound C group (C, D: two‐way analysis of variance; B, E–H, J: one‐way analysis of variance followed by Tukey’s multiple comparisons tests). AMPK: Adenosine 5′-monophosphate-activated protein kinase; CCI: chronic constrictive injury; DAPI: 4′,6-diamidino-2-phenylindole; Iba-1: ionized calcium binding adaptor molecule-1; p-AMPK: phosphorylated AMPK(Thr172); p-p38: phospho-p38 mitogen-activated protein kinase; p-STAT3: phospho-STAT3; rTSMS: repetitive trans-spinal magnetic stimulation; SOCS3: suppressor of cytokine signaling 3; STAT3: transducer and activator of transcription 3.

Article Snippet: Intrathecal injections of compound C, an adenosine 5′-monophosphate-activated protein kinase (AMPK) inhibitor (10 μg/10 μL; MedChemExpress, Newark, NJ, USA, Cat# HY-13418A), and SOCS3 siRNA (500 pmol/10 μL; Santa Cruz Biotechnology, Santa Cruz, CA, USA, Cat# SC-270156) were performed as described previously by Mestre et al. (1994).

Techniques: Activation Assay, Western Blot, Injection, Immunofluorescence, Binding Assay